Caitlin S. Briggs, MD

Assistant Professor, Department of Psychiatry

Child and Adolescent Psychiatry Division, University of Kentucky

 

Wednesday, September 10, 2025

8:00 - 9:00 AM EDT

Zoom only: https://uky.zoom.us/j/89948846670

 

Upon completion of this activity, participants will be able to:

  1. Describe diagnostic approach and key steps and components when evaluating children and adolescents for ADHD
  2. Distinguish ADHD from possible "mimic" diagnoses commonly managed by child neurology
  3. Discuss psychopharmacological strategies using current FDA-approved medications for youth with ADHD, especially with comorbid common neurological conditions
  4. Summarize common non-pharmacological interventions for youth with ADHD

 

Disclosure of Financial Interest Summary

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

None of the planners, faculty, and others in control of educational content for this educational activity have a relevant financial relationship(s) to disclose with ineligible companies.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include a discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Session date: 
09/10/2025 - 8:30am EDT to 11/09/2025 - 11:59pm EST
  • 1.00 ACPE

    In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.

    This knowledge-based activity will award 1.00 contact hour(s) (0.100 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.

  • 1.00 AMA PRA Category 1 Credit

    In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.

    This Enduring activity is designated for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

  • 1.00 ANCC (UK Healthcare CECentral)

    In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.

    The maximum number of hours awarded for this Continuing Nursing Education activity is 1.00 nursing contact hour(s).

Please login or register to take this course.